Liaise with pathologists to refine understanding of the prostate-specific antigen test

• 1 Faculty of Health Sciences and Medicine, Bond University, Gold Coast, QLD.
• 2 Centre for Research in Evidence-Based Practice, Bond University, Gold Coast, QLD.

---

• 1. Sikaris KA, Ross BA, Khong TY. Liaise with pathologists to refine understanding of the prostate-specific antigen test. Med J Aust 2013; 199: 656-658. <MJA full text>
• 2. Del Mar CB, Glasziou PP, Hirst GH, et al. Should we screen for prostate cancer? A re-examination of the evidence. Med J Aust 2013; 198: 525-527. <MJA full text>
• 3. Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
• 4. Haines IE, Gabor Miklos GL. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. J Natl Cancer Inst 2013; 105: 1534-1539.
• 5. Royal College of Pathologists of Australasia. Prostate specific antigen testing: age-related interpretation in early prostate cancer. http://www.rcpa.edu.au/search-result.aspx?searchtext=Prostate+Specific+Antigen+Testing%3a+Age-related+Interpretation&searchmode=allwords (accessed Feb 2014).
• 6. Whitaker HC, Shiong LL, Kay JD, et al. N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype. Oncogene 2013; Nov 18 [Epub ahead of print]. doi: 10.1038/onc.2013.464.
• 7. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-757.